For Oral Use
PROCARDIA® (nifedipine) is an antianginal drug belonging to a class of pharmacological agents, the calcium channel blockers.
I. Vasospastic Angina
PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers.
(Classical Effort-Associated Angina)
PROCARDIA is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents.
In chronic stable angina (effort-associated angina) PROCARDIA has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete.
Controlled studies in small numbers of patients suggest concomitant use of PROCARDIA and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See WARNINGS.)
Published Studies Related to Procardia (Nifedipine)
Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II
essential hypertension: a randomized placebo-controlled trial. 
the treatment of patients with essential hypertension... CONCLUSIONS: Vitamin D supplementation can reduce blood pressure in patients with
Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy:
a randomized controlled trial. 
hypertensive emergency of pregnancy... CONCLUSION: As administered in this trial, oral nifedipine lowered blood pressure
Effect of nifedipine on choroidal blood flow regulation during isometric
healthy subjects... CONCLUSIONS: In conclusion, the data of the present study suggest that nifedipine
Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. [2011.11]
Intravenous hydralazine is a commonly administered arteriolar vasodilator that is effective for hypertensive emergencies associated with pregnancy...
Adjuvant Tamsulosin or Nifedipine After Extracorporeal Shock Wave Lithotripsy for Renal Stones: A Double Blind, Randomized, Placebo-controlled Trial. [2011.11]
OBJECTIVE: To evaluate the effects of the adjuvant use of tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for nonlower pole kidney stones 5-20 mm in size... CONCLUSION: The stone-free rates after extracorporeal shock wave lithotripsy with adjuvant tamsulosin or nifedipine were significantly increased only for nonlower pole renal stones 10-20 mm in size compared with placebo. Nifedipine was associated with more adverse effects than placebo. Copyright A(c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Procardia (Nifedipine)
Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension [Completed]
This study compares the effect of Adalat LA to Coracten on drug levels as well as changes in
blood pressure and heart rate in fed hypertensive subjects. Subjects are dosed with either
Adalat or Coracten for first 2 weeks, followed by the other drug for 2 weeks, and then
switched back to the original drug for one day. Blood samples, blood pressure, and heart
rate are taken before and after each treatment period.
The Pharmacokinetics of Nifedipine Controlled Release Tablets in Hypertensive Patients on Hemodialysis [Not yet recruiting]
This is a prospective, open, non-randomized, non-controlled study. 20 patients with
hypertension on chronic maintenance hemodialysis will be enrolled in the study. All patients
had mild to moderate hypertension and are receiving antihypertensive agents.
This study was designed to investigate effects of Adalat GITS on hemodialytic blood
pressures in patients with chronic hemodialysis by using ABPM and measuring the drug plasma
concentrations. For the purpose of investigating the influence of hemodialysis on the drug
plasma concentration as well as its efficacy, it should be necessary to assign the subjects
with the Adalat monotherapy. Since most patients in the hemodialysis center will be those
who need and already receive combination therapy, it would be practical to start Adalat
60mg/day monotherapy to remain similar antihypertensive effect when discontinuing the
previous treatment in this study population to be screened and enrolled. And taking into
the consideration of clinical practice, few patients undergoing hemodialysis could be well
controlled by low dose Adalat 30mg/day alone. So this study will evaluate the effect and
safety of Adalat GITS 60mg/day alone and thereafter the influence of hemodialysis on the
drug plasma concentration without any other possible drug interaction. The agents are given
orally once a day at 08: 00h and patients are followed for at least 4 weeks. After that,the
patients whose blood pressure are well controlled by Adalat GITS 60mg/day by office blood
pressure would be enrolled for further ABPM assessment and plasma concentration evaluation.
Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension [Recruiting]
This will be a multi-center, prospective, randomized, open-label, parallel design, two arm
comparator trial. In the proposed study, the investigators will compare low-dose combination
therapy of Nifedipine GITS/OROS plus Valsartan with up-titrated monotherapy of Valsartan
with respect to their blood pressure-decreasing effects in patients with essential
hypertension. The study consists of a screening visit, followed by randomization and
administration of either Nifedipine GITS/OROS 30 mg in combination with Valsartan 80 mg or
Valsartan 160 mg for 12 weeks of treatment. The primary efficacy parameters will be mean SBP
and DBP on office BP monitoring at 12 weeks of treatment compared to baseline.
An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects [Recruiting]
This is an open label study. The study will consist of 1 treatment group: coated Nifedipine
suppository containing 12 mg of Nifedipine, administered BID to subjects with chronic anal
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension [Recruiting]
The purpose of this study is to determine the blood pressure lowering responses of various
dose combinations of nifedipine GITS and candesartan as compared to treatment with each
component on their own (monotherapy) and placebo (a look-alike tablet without active
ingredient). The drugs - nifedipine GITS and candesartan - which are being investigated are
currently approved for use in patients with essential hypertension alone or together with
other antihypertensive drugs (combination therapy), but the optimal dose of nifedipine GITS
and candesartan used together in the treatment of essential hypertension has not been
established yet. In this study patients will be treated with various doses of nifedipine
GITS and/or candesartan or placebo. These different regimes will be administered once a day
and will be assessed based on their blood pressure lowering effects (mean sitting diastolic
blood pressure) in subjects with mild to moderate essential hypertension.
Reports of Suspected Procardia (Nifedipine) Side Effects
Myocardial Infarction (10),
Drug Hypersensitivity (8),
Confusional State (6),
Abdominal Pain Upper (6),
Vision Blurred (6),
Rash (5), more >>
Page last updated: 2014-11-30